The overall survival of rectal NET patients with SSTR2 expression was significantly better than those without SSTR2 expression [hazard ration (HR) 0.346; 95% confidential interval (CI) 0.157–0.759; p = 0.006]. This evidence concerns the gene SSTR2 and rectum neuroendocrine neoplasm.